Prevalence and pattern of antipsychotic induced movement disorders in a tertiary care teaching hospital in India – a cross-sectional study

References

• Bakker, P. R., de Groot, I. W., van Os, J., & van Harten, P. N. (2013). Predicting the incidence of antipsychotic-induced movement disorders in long-stay patients: A prospective study. Epidemiology and Psychiatric Sciences, 22, 375–379. doi:10.1017/S204579601300019X
   PubMed Web of Science ®Google Scholar
• Barnes, T. R. E. (1989). A rating scale for drug-induced akathisia. British Journal of Psychiatry, 154, 672–676. doi:10.1192/bjp.154.5.672
   PubMed Web of Science ®Google Scholar
• Bender, S., Grohmann, R., Engel, R. R., Degner, D., Dittmann-Balcar, A., & Rüther, E. (2004). Severe adverse drug reactions in psychiatric inpatients treated with neuroleptics. Pharmacopsychiatry, 37(Suppl1), S46–S53. doi:10.1055/s-2004-815510
   Web of Science ®Google Scholar
• Caroff, S. N., Hurford, I., Lybrand, J., & Campbell, E. C. (2011). Movement disorders induced by antipsychotic drugs: Implications of the CATIE schizophrenia trial. Neurologic Clinics, 29, 127–148. doi:10.1016/j.ncl.2010.10.002
   PubMed Web of Science ®Google Scholar
• Divac, N., Prostran, M., Jakovcevski, I., & Cerovac, N. (2014). Second-generation antipsychotics and extrapyramidal adverse effects. BioMed Research International, 2014, 656370. doi:10.1155/2014/656370
   PubMed Web of Science ®Google Scholar
• Edwards, S. J., & Smith, C. J. (2009). Tolerability of atypical antipsychotics in the treatment of adults with schizophrenia or bipolar disorder: A mixed treatment comparison of randomized controlled trials. Clinical Therapeutics, 31, 1345–1359. doi:10.1016/j.clinthera.2009.07.004
   PubMed Web of Science ®Google Scholar
• Gebhardt, S., Härtling, F., Hanke, M., Mittendorf, M., Theisen, F. M., Wolf-Ostermann, K., … Remschmidt H. (2006). Prevalence of movement disorders in adolescent patients with schizophrenia and in relationship to predominantly atypical antipsychotic treatment. European Child & Adolescent Psychiatry, 15, 371–382. doi:10.1007/s00787-006-0544-5
   PubMed Web of Science ®Google Scholar
• Geddes, J., Freemantle, N., Harrison, P., & Bebbington, P. (2000). Atypical antipsychotics in the treatment of schizophrenia: Systematic overview and meta-regression analysis. BMJ, 321, 1371–1376. doi:10.1136/bmj.321.7273.1371
   PubMed Web of Science ®Google Scholar
• Gentile, S. (2007). Extrapyramidal adverse events associated with atypical antipsychotic treatment of bipolar disorder. Journal of Clinical Psychopharmacology, 27, 35–45. doi:10.1097/01.jcp.0000246217.34024.53
   PubMed Web of Science ®Google Scholar
• Ghaemi, S. N., Hsu, D. J., Rosenquist, K. J., Pardo, T. B., & Goodwin, F. K. (2006). Extrapyramidal side effects with atypical neuroleptics in bipolar disorder. Progress in Neuro-Psychopharmacology & Biological Psychiatry, 30, 209–213. doi:10.1016/j.pnpbp.2005.10.014
   PubMed Web of Science ®Google Scholar
• Greil, W., Häberle, A., Schuhmann, T., Grohmann, R., & Baumann, P. (2013). Age and adverse drug reactions from psychopharmacological treatment: Data from the AMSP drug surveillance programme in Switzerland. Swiss Medical Weekly, 143, w13772. doi:10.1016/S0924-9338(13)75915-7
   PubMed Web of Science ®Google Scholar
• Guy, W. (1976). ECDEU assessment manual for psychopharmacology. Washington: Department of Health, Education and Welfare.
   Google Scholar
• Halliday J, Farrington S, Macdonald S, MacEwan T, Sharkey V, McCreadie R. 2002. Nithsdale Schizophrenia Surveys 23: movement disorders. 20-year review. Br. J. Psychiatry. 181, 422–427. doi:10.1192/bjp.181.5.422
   PubMed Web of Science ®Google Scholar
• Hashimoto Y, Uno J, Miwa T, Kurihara M, Tanifuji H, Tensho M. 2012. Effects of antipsychotic polypharmacy on side-effects and concurrent use of medications in schizophrenic outpatients. Psychiatry Clin. Neurosci, 66, 405–410. doi:10.1111/j.1440-1819.2012.02376.x
   PubMed Web of Science ®Google Scholar
• ICH E2A guideline. (2017, March 28). Note for guidance on clinical safety data management: definitions and standards for expedited reporting. Retrived from http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E2A/Step4/E2A_Guideline.pdf.
   Google Scholar
• Iuppa, C. A., Nelson, L. A., Elliott, E., & Sommi, R. W. (2013). Adverse drug reactions: A retrospective review of hospitalized patients at a state psychiatric hospital. Hospital Pharmacy, 48, 931–935. doi:10.1310/hpj4811-931
   PubMedGoogle Scholar
• Janno, S., Holi, M., Tuisku, K., & Wahlbeck, K. (2004). Prevalence of neuroleptic-induced movement disorders in chronic schizophrenia inpatients. American Journal of Psychiatry, 161, 160–163. doi:10.1176/appi.ajp.161.1.160
   PubMed Web of Science ®Google Scholar
• Lerner, V., Libov, I., Kaptsan, A., Miodownik, C., Dwolatzky, T., & Levine, J. (2007). The prevalence of neuroleptic drug-induced tardive movement subsyndromes among schizophrenic and schizoaffective patients residing in the southern region of Israel. Israel Journal of Psychiatry and Related Sciences, 44, 20–28.
   PubMed Web of Science ®Google Scholar
• Lieberman, J. A., Stroup, T. S., McEvoy, J.P., Swartz, M. S., Rosenheck, R. A., Perkins, D. O., … Hsiao, J. K. (2005). Clinical antipsychotic trials of intervention effectiveness (CATIE) investigators: Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. New England Journal of Medicine, 353, 1209–1223. doi:10.1056/NEJMoa051688
   PubMed Web of Science ®Google Scholar
• Lucca, J. M., Ramesh, M., Ram, D., & Kishor, M. (2016). Incidence and predictors of adverse drug reactions caused by drug–drug interactions in psychiatric patients: an empirical study. Tropical Journal of Medical Research, 19, 29–35. doi:10.4103/1119-0388.172059
   Google Scholar
• Mandal, A., Chatterjee, S., Das, S. K., & Mishra, A. (2010). Drug safety monitoring in patients of movement disorders of a tertiary care hospital. Indian Journal of Pharmacology, 42, 249–251. doi:10.4103/0253-7613.68437
   PubMed Web of Science ®Google Scholar
• Miller, D. D., McEvoy, J. P., Davis, S. M., Caroff, S. N., Saltz, B. L., Chakos, M. H., … Lieberman, J. A. (2005). Clinical correlates of tardive dyskinesia in schizophrenia: Baseline data from the CATIE schizophrenia trial. Schizophrenia Research, 80, 33–43. doi:10.1016/j.schres.2005.07.034
   PubMed Web of Science ®Google Scholar
• Minzenberg, M. J., Poole, J. H., Benton, C., & Vinogradov, S. (2004). Association of anticholinergic load with impairment of complex attention and memory in schizophrenia. American Journal of Psychiatry, 161, 116–124. doi:10.1176/appi.ajp.161.1.116
   PubMed Web of Science ®Google Scholar
• Muench, J., & Hamer, A. M. (2010). Adverse effects of antipsychotic medications. American Family Physician, 81, 617–622.
   PubMed Web of Science ®Google Scholar
• Nasrallah, H. A., Brecher, M., & Paulsson, B. (2006). Placebo-level incidence of extrapyramidal symptoms (EPS) with quetiapine in controlled studies of patients with bipolar mania. Bipolar Disorders, 8, 467–474. doi:10.1111/j.1399-5618.2006.00350.x
   PubMed Web of Science ®Google Scholar
• Ogino, S., Miyamoto, S., Miyake, N., & Yamaguchi, N. (2014). Benefits and limits of anticholinergic use in schizophrenia: Focusing on its effect on cognitive function. Psychiatry and Clinical Neurosciences, 68, 37–49. doi:10.1111/pcn.12088
   PubMed Web of Science ®Google Scholar
• Parksepp, M., Ljubajev, Ü., Täht, K., & Janno, S. (2016). Prevalence of neuroleptic-induced movement disorders: An 8-year follow-up study in chronic schizophrenia inpatients. Nordic Journal of Psychiatry, 70, 498–502. doi:10.3109/08039488.2016.1164245
   PubMed Web of Science ®Google Scholar
• Patel, T. K., Bhabhor, P. H., Desai, N., Shah, S., Patel, P. B., Vatsala, E., … Panigrahi, S. (2015). Adverse drug reactions in a psychiatric department of tertiary care teaching hospital in India: Analysis of spontaneously reported cases. Asian Journal of Psychiatry, 17, 42–49. doi:10.1016/j.ajp.2015.07.003
   PubMed Web of Science ®Google Scholar
• Patel, T. K., & Patel, P. B. (2016). Incidence of adverse drug reactions in Indian hospitals: A systematic review of prospective studies. Current Drug Safety, 11, 128–136. doi:10.2174/1574886310666150921104523
   PubMed Web of Science ®Google Scholar
• Pierre, J. M. (2005). Extrapyramidal symptoms with atypical antipsychotics: Incidence, prevention and management. Drug Safety, 28, 191–208. doi:10.2165/00002018-200528030-00002
   PubMed Web of Science ®Google Scholar
• Sadock, B. J., Sadock, V.A., & Ruiz, P. (2016). Kaplan & Sadock’s synopsis of psychiatry: behavioral sciences/clinical psychiatry. Psychopharmacological treatment. New Delhi: Walters Kluwer.
   Google Scholar
• Schooler, N. R., & Kane, J. M. (1982). Research diagnoses for tardive dyskinesia. Archives of General Psychiatry, 39, 486–487. doi:10.1001/archpsyc.1982.04290040080014
   PubMed Web of Science ®Google Scholar
• Schumock, G. T., & Thornton, J. P. (1992). Focusing on the preventability of adverse drug reactions. Hospital Pharmacy, 27, 538.
   PubMedGoogle Scholar
• Simpson, G. M., & Angus, J. W. (1970). A rating scale for extrapyramidal side effects. Acta Psychiatrica Scandinavica Supplementum, 212, 11–19. doi:10.1111/j.1600-0447.1970.tb02066.x
   PubMedGoogle Scholar
• Tarsy, D., Baldessarini, R., & Tarazi, F. (2002). Effects of newer antipsychotics on extrapyramidal function. CNS Drugs, 16, 23–24. doi:10.2165/00023210-200216010-00003
   PubMed Web of Science ®Google Scholar
• Thanvi, B., & Treadwell, S. (2009). Drug induced parkinsonism: A common cause of parkinsonism in older people. Postgraduate Medical Journal, 85, 322–326. doi:10.1136/pgmj.2008.073312
   PubMed Web of Science ®Google Scholar
• The use of the WHO-UMC system for standardised case causality assessment. (2017, March 10). Retrieved from https://www.who-umc.org/media/2768/standardised-case-causality-assessment.pdf
   Google Scholar
• van Harten, P. N., Matroos, G. E., Hoek, H. W., & Kahn, R. S. (1996). The prevalence of tardive dystonia, tardive dyskinesia, parkinsonism and akathisia The Curaçao Extrapyramidal Syndromes Study: I. Schizophrenia Research, 19, 195–203. doi:10.1016/0920-9964(95)00096-8
   PubMed Web of Science ®Google Scholar